Back to home
REGN logo

Is REGN (Regeneron Pharmaceuticals, Inc.) Halal or Haram?

NASDAQ Global SelectHealthcareBiotechnology$76.03B2026-04-29
REGN is Halal4/4 screens passed

Regeneron Pharmaceuticals successfully passes all AAOIFI Shariah screens, making it a Halal investment. The company's debt-to-market cap ratio is exceptionally low at 3.6%, and its cash-to-market cap sits comfortably at 11.3%. However, investors should note that interest income to revenue is exactly on the borderline at 5.00%, requiring close monitoring in future quarters.

Price Chart (5D)

$701.04-44.58 (-5.98%)
2026-05-012026-04-24

REGN — Last 7 Days

DateOpenHighLowCloseVolumeChange
2026-05-01703.02714.48700.26701.42729K-0.23%
2026-04-30693.08708.44688.95707.061.1M+2.02%
2026-04-29705.11708.80668.85686.361.8M-2.66%
2026-04-28751.37754.00730.90731.77569K-2.61%
2026-04-27745.47756.40743.61744.44603K-0.14%
2026-04-24760.00761.96736.71751.57810K-1.11%
2026-04-23750.99767.21747.26766.02929K+2.00%

Discussion

Sign in to join the discussion

Loading comments...

Shariah Screening Details for REGN

Business Activity

Permissible

Regeneron's business activity passes Shariah screening as its core operations involve developing and manufacturing permissible life-saving medicines, such as EYLEA for eye diseases and Dupixent for asthma.

Debt / Market Cap

3.56%

Debt: $2.71BThreshold: ≤33%

Interest Income

5.00%

Interest: $716.8MThreshold: ≤5%

Cash & Securities

11.32%

Cash: $8.61BThreshold: ≤33%

About Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. is a leading biotechnology company that discovers and commercializes medicines for serious medical conditions. Its flagship products include EYLEA, an injection used to treat retinal diseases like macular degeneration, and Dupixent, a widely used treatment for atopic dermatitis and asthma.

For Muslim investors, Regeneron represents a Halal investment opportunity within the healthcare sector, having successfully passed all four AAOIFI screening criteria. The company's core business of developing therapeutic medicines is fundamentally permissible, aligning well with Islamic principles of preserving life and health.

From an Islamic finance perspective, Regeneron boasts an incredibly strong balance sheet with a debt-to-market cap ratio of just 3.6%, well below the 33% threshold. Its cash and interest-bearing securities also pass comfortably at 11.3% of its market capitalization, indicating minimal reliance on conventional, interest-based leverage.

While the stock is currently compliant, halal investors must pay strict attention to Regeneron's interest income, which currently sits exactly at the 5.00% AAOIFI maximum limit. Any slight increase in interest-generating cash equivalents could push the stock into non-compliant territory in upcoming earnings reports, making routine dividend purification and quarterly monitoring essential.

CEO

Leonard S. Schleifer

Employees

15,158

IPO Date

1991-04-02

Headquarters

Tarrytown, NY, US

REGN Key Financial Statistics

Revenue

$14.34B

Net Income

$4.50B

EPS (Diluted)

$41.48

Stock Price

731.77

Beta

0.40

52-Week Range

476.49-821.11

Total Debt

$2.71B

Total Equity

$31.26B

Current Ratio

4.13

REGN Financial Health & Profitability

Profit Margins

Gross Margin85.4%
Operating Margin24.9%
Net Margin31.4%

Revenue Growth (YoY)

+1.0%

Prior year: $14.20B

Net Cash

$412.2M

Cash: $3.12B — Debt: $2.71B

R&D Spending

$5.85B

% of Revenue

40.8%

Frequently Asked Questions About REGN

Is REGN (Regeneron Pharmaceuticals, Inc.) stock halal to invest in?
Based on our AAOIFI-standard shariah screening, REGN is Halal and considered permissible for Muslim investors. It passed all 4 of 4 compliance screens including business activity review, debt-to-market-cap ratio (3.56% vs ≤33% threshold), interest income ratio (5.00% vs ≤5% threshold), and cash & securities ratio (11.32% vs ≤33% threshold).
What does Regeneron Pharmaceuticals, Inc. do?
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company that discovers and commercializes medicines for serious medical conditions. Its flagship products include EYLEA, an injection used to treat retinal diseases like macular degeneration, and Dupixent, a widely used treatment for atopic dermatitis and asthma. For Muslim investors, Regeneron represents a Halal investment opportunity within the healthcare sector, having successfully passed all four AAOIFI screening criteria. The company's core business of developing therapeutic medicines is fundamentally permissible, aligning well with Islamic principles of preserving life and health. From an Islamic finance perspective, Regeneron boasts an incredibly strong balance sheet with a debt-to-market cap ratio of just 3.6%, well below the 33% threshold. Its cash and interest-bearing securities also pass comfortably at 11.3% of its market capitalization, indicating minimal reliance on conventional, interest-based leverage. While the stock is currently compliant, halal investors must pay strict attention to Regeneron's interest income, which currently sits exactly at the 5.00% AAOIFI maximum limit. Any slight increase in interest-generating cash equivalents could push the stock into non-compliant territory in upcoming earnings reports, making routine dividend purification and quarterly monitoring essential. Regeneron Pharmaceuticals, Inc. operates in the Healthcare sector under the Biotechnology industry and is headquartered in Tarrytown, NY, US. The company is led by CEO Leonard S. Schleifer and employs approximately 15,158 people.
What screening criteria were used for REGN?
REGN was screened using AAOIFI-based shariah compliance criteria. Four tests are applied: (1) Business Activity — the company's core business must not derive primary income from haram (prohibited) activities such as alcohol, gambling, tobacco, or interest-based finance. (2) Debt-to-Market-Cap — total debt must not exceed 33% of market capitalization. (3) Interest Income — interest income must not exceed 5% of total revenue. (4) Cash & Securities — cash and interest-bearing securities must not exceed 33% of market cap. REGN passed 4 of these 4 screens.
Does REGN require income purification?
Although REGN passes all shariah screens, it does earn $716.8M in interest income (5.00% of revenue). Many scholars recommend purifying this portion by donating the equivalent percentage of any dividends received to charity. For example, if you receive $100 in dividends, you would donate approximately $5.00 to purify the income.
When was REGN last screened?
REGN was last screened on 2026-04-29. Shariah compliance status can change as companies report new financial data, acquire new businesses, or shift revenue streams. We recommend checking back periodically for the most up-to-date screening results.

Disclaimer

This shariah compliance assessment for REGN (Regeneron Pharmaceuticals, Inc.) is provided for informational purposes only and does not constitute financial, investment, or religious advice. Screening criteria are based on widely accepted AAOIFI standards, but individual scholars may differ in their opinions. Always consult with a qualified Islamic scholar and licensed financial advisor before making investment decisions. Past screening status does not guarantee future compliance. Last screened: 2026-04-29.

Other Halal Stocks in Healthcare